SciTech Development Announces First Patient Dosed in Phase 1 Trial of ST-001
SciTech Development Announces Activation of First Three Clinical Trial Sites
GROSSE POINTE FARMS, Mich., Oct. 3, 2023 /PRNewswire/ --.SciTech announced today that it has successfully manufactured the clinical supply of its lead drug candidate, ST-001 nanoFenretinide, to initiate its upcoming clinical trial in T-cell non-Hodgkin lymphomas (NCT04234048).